Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-09-25 , DOI: 10.1111/apt.16600
Kang Chao _{1,

2} , Yibiao Huang ₃ , Xia Zhu _{1,

2,

4} , Jian Tang _{1,

2} , Xueding Wang ₄ , Lang Lin _{1,

2} , Huili Guo _{1,

2} , Caibin Zhang ₄ , Miao Li _{1,

2} , Qingfan Yang _{1,

2} , Jie Huang _{1,

2} , Lingna Ye ₃ , Pinjin Hu _{1,

2} , Min Huang ₄ , Qian Cao ₃ , Xiang Gao _{1,

2}

Affiliation

Thiopurine S-methyltransferase (TPTM) is a well known biomarker for thiopurine-induced leucopenia, which has limited value in Asia. Instead, NUDT15 C415T is a promising predictor in Asia.

中文翻译：